Filing Flows › Comparisons › AKBA vs VTVT
Akebia Therapeutics vs vTv Therapeutics: AKBA and VTVT compared
Akebia Therapeutics is the larger company: $36.9M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026). vTv Therapeutics is more profitable, with an operating margin of 63.1% against -31.1%.
Where the money goes: AKBA and VTVT
Akebia Therapeutics (AKBA) · Q3 2026
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
vTv Therapeutics (VTVT) · Q1 2026
vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%, net earnings $24.1M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
| Akebia Therapeutics (AKBA) | vTv Therapeutics (VTVT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2026 |
| Revenue | $36.9M | $36.8M |
| Revenue growth, Y/Y | -37% | — |
| Operating margin | -31.1% | 63.1% |
| Net earnings | −$14.4M | $24.1M |
| Net margin | -38.9% | 65.5% |
| Operating cash flow | $2.3M | $9.2M |
| Free cash flow | $1.6M | — |
Where the revenue comes from
Akebia Therapeutics
- Product revenue, net: $34.8M (94%)
- License, collaboration and other revenue: $2.1M (6%)
Questions
Which is bigger, Akebia Therapeutics or vTv Therapeutics?
Akebia Therapeutics is the larger company: $36.9M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026).
Is Akebia Therapeutics or vTv Therapeutics growing faster?
vTv Therapeutics is more profitable, with an operating margin of 63.1% against -31.1%.
More: Akebia Therapeutics earnings · how Akebia Therapeutics makes money · vTv Therapeutics earnings · how vTv Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed May 13, 2026). Fiscal quarters can end on different dates. Not investment advice.